JP2020532987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532987A5 JP2020532987A5 JP2020513604A JP2020513604A JP2020532987A5 JP 2020532987 A5 JP2020532987 A5 JP 2020532987A5 JP 2020513604 A JP2020513604 A JP 2020513604A JP 2020513604 A JP2020513604 A JP 2020513604A JP 2020532987 A5 JP2020532987 A5 JP 2020532987A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- transgene
- sequence
- ligand
- inducible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700019146 Transgenes Proteins 0.000 claims 17
- 239000003446 ligand Substances 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 230000001939 inductive effect Effects 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 101710204410 Scaffold protein Proteins 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 claims 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 claims 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076622A JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556310P | 2017-09-08 | 2017-09-08 | |
| US62/556,310 | 2017-09-08 | ||
| PCT/US2018/050288 WO2019051424A2 (en) | 2017-09-08 | 2018-09-10 | COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076622A Division JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532987A JP2020532987A (ja) | 2020-11-19 |
| JP2020532987A5 true JP2020532987A5 (enExample) | 2021-10-21 |
Family
ID=64270934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513604A Pending JP2020532987A (ja) | 2017-09-08 | 2018-09-10 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| JP2024076622A Pending JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076622A Pending JP2024109657A (ja) | 2017-09-08 | 2024-05-09 | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12385061B2 (enExample) |
| EP (1) | EP3679145A2 (enExample) |
| JP (2) | JP2020532987A (enExample) |
| CN (1) | CN111727256A (enExample) |
| AU (2) | AU2018329741B2 (enExample) |
| CA (1) | CA3072777A1 (enExample) |
| WO (1) | WO2019051424A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12202856B2 (en) | 2016-05-19 | 2025-01-21 | The General Hospital Corporation | Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| JP2020532987A (ja) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス，インコーポレイティド | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3121247A1 (en) | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| MX2021013218A (es) * | 2019-05-01 | 2021-12-10 | Pact Pharma Inc | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. |
| JP7715640B2 (ja) * | 2019-05-03 | 2025-07-30 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異染性白質ジストロフィーの治療に有用な組成物 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| EP3753566A1 (en) * | 2019-06-21 | 2020-12-23 | Medizinische Hochschule Hannover | All-in one viral vector for car and therapeutic effector molecule |
| EP4010361A4 (en) * | 2019-08-06 | 2023-08-09 | Children's Medical Center Corporation | METHODS AND COMPOSITIONS FOR RESTORING MICROGLIA |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| BR112022010460A2 (pt) * | 2019-12-02 | 2022-09-06 | Lg Chemical Ltd | Fatores secretores de proteína derivada de células de cho e vetores de expressão compreendendo os mesmos |
| KR102937659B1 (ko) | 2020-02-19 | 2026-03-10 | 우시 바이올로직스 아일랜드 리미티드 | 강화된 발현 시스템 및 그 사용방법 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021207526A1 (en) | 2020-04-09 | 2021-10-14 | The Regents Of The University Of California | Humanized notch receptors with hinge domain |
| US20230167464A1 (en) * | 2020-04-27 | 2023-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity |
| WO2021234662A1 (en) * | 2020-05-21 | 2021-11-25 | Crispr Therapeutics Ag | Genetically engineered car t cells that secrete interleukin-12 and therapeutic uses thereof |
| TW202220677A (zh) * | 2020-07-31 | 2022-06-01 | 日商中外製藥股份有限公司 | 含有表現嵌合受體之細胞的醫藥組成物 |
| WO2022226375A1 (en) * | 2021-04-23 | 2022-10-27 | Locanabio, Inc. | Tissue-targeted modified aav capsids and methods of use thereof |
| EP4082560B1 (en) * | 2021-04-27 | 2025-02-26 | Academia Sinica | Prap1 polypeptide for use in treating hypertriglyceridemia |
| CN117915930A (zh) * | 2021-04-28 | 2024-04-19 | 总医院公司 | 与其受体IL-2Rβ结合的IL2以及成孔蛋白作为增强免疫细胞活性的平台 |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| EP4373845A4 (en) * | 2021-07-23 | 2025-06-25 | The Children's Medical Center Corporation | Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use |
| JP2024531910A (ja) * | 2021-08-04 | 2024-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法 |
| CN114940974A (zh) * | 2021-09-28 | 2022-08-26 | 宁波熙宁检测技术有限公司 | 4-1bb报告基因293t稳转细胞株构建和应用 |
| WO2023109911A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Microglia having car and use thereof |
| CN115216492B (zh) * | 2022-06-29 | 2023-05-30 | 浙江欧赛思生物科技有限公司 | 一种小鼠原发神经胶质瘤模型的制备方法及其应用 |
| GB202219568D0 (en) * | 2022-12-22 | 2023-02-08 | Autolus Ltd | Chimeric antigen receptor |
| WO2025070635A1 (ja) * | 2023-09-27 | 2025-04-03 | 味の素株式会社 | 免疫細胞培養用培地 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
| US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
| US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
| US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2109945T3 (es) | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
| ATE248583T1 (de) | 1997-09-29 | 2003-09-15 | Nektar Therapeutics | In dosierinhalatoren verwendbare, stabilisierte zubereitungen |
| JP2003135078A (ja) * | 2001-07-26 | 2003-05-13 | Japan Tobacco Inc | Ｃ型肝炎ウイルスｎｓ５ａタンパク質の変異体、およびその利用 |
| JP2007517491A (ja) * | 2003-12-29 | 2007-07-05 | 株式会社東京大学Ｔｌｏ | 免疫調節剤を同定する方法、免疫調節剤、およびこれらの使用法 |
| WO2006133398A2 (en) | 2005-06-08 | 2006-12-14 | Invitrogen Corporation | In vitro activated donor t-cells to promote transplant engraftment |
| US9228180B2 (en) | 2007-07-04 | 2016-01-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | Polypeptide variants of sleeping beauty transposase |
| WO2010126766A1 (en) | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| FR2952374B1 (fr) * | 2009-11-06 | 2012-11-16 | Univ Claude Bernard Lyon | Production de facteur ix recombinant dans une lignee cellulaire hepatocytaire humaine |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| MX358827B (es) * | 2011-09-27 | 2018-09-05 | Janssen Biotech Inc | Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas. |
| BR112014020325A2 (pt) * | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| US10927384B2 (en) | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| CN107810420B (zh) * | 2015-06-25 | 2020-08-14 | 豪夫迈·罗氏有限公司 | 用于测定抗体或配体结合和功能的基于细胞的测定 |
| EP4339287A3 (en) * | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| GB201514875D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| JP2019506177A (ja) * | 2016-02-26 | 2019-03-07 | ポセイダ セラピューティクス， インコーポレイテッド | トランスポゾン系および使用方法 |
| WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| CA3063695A1 (en) | 2017-05-17 | 2018-11-22 | Seattle Children's Hospital (Dba Seattle Children's Research Institute | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy |
| AU2018301667A1 (en) | 2017-07-12 | 2020-02-06 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Foundation | Methods and systems for conditionally regulating gene expression |
| JP2020532987A (ja) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス，インコーポレイティド | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| CA3111384A1 (en) | 2018-09-05 | 2020-03-12 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
-
2018
- 2018-09-10 JP JP2020513604A patent/JP2020532987A/ja active Pending
- 2018-09-10 CA CA3072777A patent/CA3072777A1/en active Pending
- 2018-09-10 EP EP18800779.3A patent/EP3679145A2/en active Pending
- 2018-09-10 WO PCT/US2018/050288 patent/WO2019051424A2/en not_active Ceased
- 2018-09-10 AU AU2018329741A patent/AU2018329741B2/en active Active
- 2018-09-10 CN CN201880071587.1A patent/CN111727256A/zh active Pending
- 2018-09-10 US US16/640,788 patent/US12385061B2/en active Active
-
2024
- 2024-05-09 JP JP2024076622A patent/JP2024109657A/ja active Pending
-
2025
- 2025-05-21 AU AU2025203769A patent/AU2025203769A1/en active Pending
- 2025-07-01 US US19/257,110 patent/US20260125701A1/en active Pending
- 2025-07-01 US US19/257,090 patent/US20260125700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109657A5 (enExample) | ||
| Steeland et al. | A new venue of TNF targeting | |
| JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
| Roh-Johnson et al. | Macrophage-dependent cytoplasmic transfer during melanoma invasion in vivo | |
| Rajagopalan et al. | Activation of NK cells by an endocytosed receptor for soluble HLA-G | |
| Roybal et al. | Engineering T cells with customized therapeutic response programs using synthetic notch receptors | |
| Edwards et al. | Regulation of the expression of GARP/latent TGF-β1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation | |
| Zuccolotto et al. | PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models | |
| ES2784237T3 (es) | Receptores de células T anti-papilomavirus 16 E7 humano | |
| Miyanishi et al. | Synergistic effect of Tim4 and MFG-E8 null mutations on the development of autoimmunity | |
| Billerbeck et al. | Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice | |
| Pan et al. | Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains | |
| JP2018519296A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| CA3109354A1 (en) | Combination therapies comprising pd-1-based chimeric proteins | |
| Schnerwitzki et al. | Neuron-specific inactivation of Wt1 alters locomotion in mice and changes interneuron composition in the spinal cord | |
| US12331129B2 (en) | Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof | |
| Chen et al. | Targeting the IGF-axis for cancer therapy: development and validation of an IGF-trap as a potential drug | |
| Okada et al. | Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels: A lentiviral vector approach | |
| CN117500823A (zh) | 自身免疫中的嵌合蛋白 | |
| Cirella et al. | Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists | |
| Zhang et al. | Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy | |
| Kang et al. | In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors | |
| Lombardi et al. | MET oncogene targeting for cancer immunotherapy |